Sponsor:
Fox Chase Cancer Center
Code:
NCT06396533
Conditions
Urothelial Carcinoma
Muscle Invasive Bladder Urothelial Carcinoma
Non-Muscle Invasive Bladder Urothelial Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Brief summary:
Conditions
Urothelial Carcinoma
Muscle Invasive Bladder Urothelial Carcinoma
Non-Muscle Invasive Bladder Urothelial Carcinoma
Study ID
NCT06396533
Start date
Aug 13, 2024
Status verified date
Oct, 2025
Completion date
Feb 23, 2029
Anticipated
Primary completion date
Apr 23, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
92 participants
Anticipated
Arms
Non- neoadjuvant chemotherapy patients
Neoadjuvant Chemotherapy (NAC) Patients
Primary outcome measure
Central contacts
Locations
University of Nebraska Medical Center
Recruiting
Omaha, Nebraska, United States, 68198
Principal Investigator:
Jared Schober, MD
Fox Chase Cancer Center
Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contacts
Sponsor
Fox Chase Cancer Center
Last update posted
Oct 31, 2025
Last verified
Oct, 2025
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-21. This information was provided to ClinicalTrials.gov by Fox Chase Cancer Center on 2025-10-31.